IBRUTINIB (ibrutinib) by AbbVie is protein kinase inhibitors [moa]. First approved in 2021.
Drug data last refreshed 19h ago
Protein Kinase Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Remibrutinib Open Label Roll-over Post-trial Access Protocol
A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
Remibrutinib in Real-world Clinical Practice - a US Sub-study
Remibrutinib in Real-world Clinical Practice
A Real-world Study of Remibrutinib in Chronic Spontaneous Urticaria Patients
Worked on IBRUTINIB at AbbVie? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.